Chardan Capital Maintains Buy on Opus Genetics, Raises Price Target to $13
Benzinga Newsdesk 4 months ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Andreas Argyrides maintains Opus Genetics (NASDAQ:IRD) with a Buy and raises the price target from $11 to $13.
Chardan Capital analyst Andreas Argyrides maintains Opus Genetics (NASDAQ:IRD) with a Buy and raises the price target from $11 to $13.